The global Epigenetics Market is estimated to be valued at US$ 14.80 Bn or Billion in 2023 and is expected to exhibit a CAGR of 1.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Epigenetics refers to changes in gene expression or phenotype that occur without alteration in the nucleotide sequence of DNA. Study of epigenetics provides advantages such as understanding how genes and environment can influence each other. Epigenetic products are useful in studying DNA methylation, histone modifications and microRNAs involved in various diseases.

Market key trends:
Growing prevalence of cancer is one of the key trends contributing to growth of the epigenetics market. According to World Health Organization (WHO), cancer accounted for nearly 10 million deaths in 2020 globally. Epigenetic techniques like DNA methylation and histone modifications help in early detection and diagnosis of cancer. Epigenetic markers are studied to identify cancers at early stages as well as understand tumor progression and behavior. With increasing cancer burden, demand for epigenetic tools and assays for biomarker identification is estimated to grow during the forecast period.
Market key trends:
The Global Epigenetics Market is witnessing increased adoption of epigenetics technology such as next-generation sequencing, polymerase chain reaction, mass spectroscopy, and microarray for epigenetic research. These technologies aid in deeper understanding of gene expression regulation and cellular response to the environment. The next-generation sequencing (NGS) technology has revolutionized disease pathogenesis research by determining epigenetic changes associated with various cancer types and other chronic diseases. Besides aiding disease diagnosis, epigenetic techniques are finding immense use in precision medicine for developing targeted therapies.

SWOT Analysis
Strength: Presence of global key players with strong technological capabilities and wide geographic presence.
Weakness: High costs associated with epigenetic instruments, reagents and services limit widespread adoption.
Opportunity: Increasing R&D investments and growing incidence of chronic diseases to drive the use of epigenetics in developing novel targeted therapies and biomarker development.
Threats: Stringent regulations for approval of epigenetic diagnostic tests and therapeutics. Concerns regarding data privacy and ethical issues pertaining to epigenome editing research.

Key Takeaways
The global epigenetics market size is expected to reach US$ 14.80 billion by 2023, expanding at a CAGR of 14.0% during the forecast period. The rising prevalence of cancer and other chronic diseases is expected to drive the demand for epigenetics technologies globally.

North America dominated the global market and is estimated to maintain its lead throughout the forecast period. Presence of key market players, developed healthcare infrastructure, and growing funding for epigenetic research are some factors responsible for North America's large market share.

Key players operating in the epigenetics market are Active Motif, Inc., Zymo Research, Thermo Fisher Scientific Inc., QIAGEN N.V., Merck Millipore, Illumina Inc., Agilent Technologies, Inc., Abcam Plc., Hologic Inc., and PerkinElmer, Inc. Major players are focusing on new product launches, expansions, mergers & acquisitions to strengthen their market position.

Read More: https://cmiresearch.blogspot.com/2023/11/the-development-of-non-invasive.html